InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GENELUX Corp

GNLX Clue Score24
United States Fiscal year ends December CIK 0001231457
$2.56 +2.40% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.56 −89.24% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Jan 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue11.1Operating income−3.0Net income−5.2EPS, diluted−0.57Fiscal year 2023Revenue0.2 −98.5%Operating income−24.2Net income−28.3EPS, diluted−1.16Fiscal year 2024Revenue0.0 −95.3%Operating income−31.7Net income−29.9EPS, diluted−0.95Fiscal year 2025Revenue0.0 +0.0%Operating income−33.2Net income−32.1EPS, diluted−0.86
FY2022FY2023FY2024FY2025
Revenue 11.1 0.2 0.0 0.0
Growth −98.5% −95.3% +0.0%
Operating income −3.0 −24.2 −31.7 −33.2
Net income −5.2 −28.3 −29.9 −32.1
Growth
EPS, diluted −0.57 −1.16 −0.95 −0.86

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Operating margin−27.2%Net margin−47.0%Free cash flow margin−32.7%Fiscal year 2023Operating margin−14,214.7%Net margin−16,645.3%Free cash flow margin−12,529.4%Fiscal year 2024Operating margin−396,200.0%Net margin−373,362.5%Free cash flow margin−270,112.5%Fiscal year 2025Operating margin−415,175.0%Net margin−401,812.5%Free cash flow margin−329,575.0%
FY2022FY2023FY2024FY2025
Operating margin −27.2% −14,214.7% −396,200.0% −415,175.0%
Net margin −47.0% −16,645.3% −373,362.5% −401,812.5%
Free cash flow margin −32.7% −12,529.4% −270,112.5% −329,575.0%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−3.6Capital expenditure−0.0Free cash flow−3.6Fiscal year 2023Operating cash flow−20.3Capital expenditure−1.0Free cash flow−21.3Fiscal year 2024Operating cash flow−21.2Capital expenditure−0.4Free cash flow−21.6Fiscal year 2025Operating cash flow−25.3Capital expenditure−1.1Free cash flow−26.4
FY2022FY2023FY2024FY2025
Operating cash flow −3.6 −20.3 −21.2 −25.3
Capital expenditure −0.0 −1.0 −0.4 −1.1
Free cash flow −3.6 −21.3 −21.6 −26.4
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.4Shareholders’ equity−35.8Fiscal year 2023Cash9.4Shareholders’ equity19.5Fiscal year 2024Cash8.6Shareholders’ equity26.3Fiscal year 2025Cash5.3Shareholders’ equity11.5
FY2022FY2023FY2024FY2025
Cash 0.4 9.4 8.6 5.3
Shareholders’ equity −35.8 19.5 26.3 11.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−3.6 −20.3 −21.2 −25.3
Growth
Investment
−0.0 −1.0 −0.4 −1.1
calc −3.6 −21.3 −21.6 −26.4
Growth
calc −0.40 −0.87 −0.69 −0.71
−0.0 −14.7 −8.1 12.1
Financing
−0.5 44.0 28.5 9.9

† The diluted share count jumps at 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.